Aquestive Therapeutics Files 8-K
Ticker: AQST · Form: 8-K · Filed: Dec 2, 2024 · CIK: 1398733
| Field | Detail |
|---|---|
| Company | Aquestive Therapeutics, Inc. (AQST) |
| Form Type | 8-K |
| Filed Date | Dec 2, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: filing, sec
Related Tickers: AQST
TL;DR
AQST filed an 8-K, check for updates.
AI Summary
On December 2, 2024, Aquestive Therapeutics, Inc. filed an 8-K report. The filing primarily concerns Regulation FD disclosures and other events, along with financial statements and exhibits. No specific material events or financial figures were detailed in the provided excerpt.
Why It Matters
This 8-K filing indicates Aquestive Therapeutics is providing updates to the SEC, which could contain material information for investors.
Risk Assessment
Risk Level: low — The provided text is a standard 8-K filing header and does not contain specific material events or financial disclosures that would indicate a high risk.
Key Players & Entities
- Aquestive Therapeutics, Inc. (company) — Registrant
- 0001398733 (company) — Central Index Key
- 2834 (company) — Standard Industrial Classification Code
- 208623253 (company) — IRS Number
- DE (company) — State of Incorporation
- 1231 (company) — Fiscal Year End
- 001-38599 (company) — SEC File Number
- 241517459 (company) — Film Number
- 30 Technology Drive (company) — Business Address Street 1
- Warren (company) — Business Address City
FAQ
What is the primary purpose of this 8-K filing by Aquestive Therapeutics, Inc.?
The 8-K filing is for Regulation FD Disclosure, Other Events, and Financial Statements and Exhibits, as of December 2, 2024.
What is Aquestive Therapeutics, Inc.'s principal executive office address?
Aquestive Therapeutics, Inc.'s principal executive offices are located at 30 Technology Drive, Warren, NJ 07059.
What is the SEC file number for Aquestive Therapeutics, Inc.?
The SEC file number for Aquestive Therapeutics, Inc. is 001-38599.
When was Aquestive Therapeutics, Inc. incorporated?
Aquestive Therapeutics, Inc. was incorporated in Delaware.
What was Aquestive Therapeutics, Inc.'s former company name?
Aquestive Therapeutics, Inc.'s former company name was MonoSol Rx, Inc., with a date of name change on May 7, 2007.
Filing Stats: 592 words · 2 min read · ~2 pages · Grade level 10.2 · Accepted 2024-12-02 08:08:12
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share AQST Nasdaq Global Market I
Filing Documents
- aqst-20241202.htm (8-K) — 29KB
- pressrelease-finalforrev.htm (EX-99.1) — 13KB
- q42024-prexndameetingsup.htm (EX-99.2) — 14KB
- pressrelease-finalforrev001.jpg (GRAPHIC) — 278KB
- pressrelease-finalforrev002.jpg (GRAPHIC) — 298KB
- pressrelease-finalforrev003.jpg (GRAPHIC) — 324KB
- pressrelease-finalforrev004.jpg (GRAPHIC) — 42KB
- q42024-prexndameetingsup001.jpg (GRAPHIC) — 90KB
- q42024-prexndameetingsup002.jpg (GRAPHIC) — 278KB
- q42024-prexndameetingsup003.jpg (GRAPHIC) — 116KB
- q42024-prexndameetingsup004.jpg (GRAPHIC) — 131KB
- q42024-prexndameetingsup005.jpg (GRAPHIC) — 112KB
- q42024-prexndameetingsup006.jpg (GRAPHIC) — 61KB
- q42024-prexndameetingsup007.jpg (GRAPHIC) — 30KB
- 0001628280-24-049497.txt ( ) — 2616KB
- aqst-20241202.xsd (EX-101.SCH) — 2KB
- aqst-20241202_lab.xml (EX-101.LAB) — 21KB
- aqst-20241202_pre.xml (EX-101.PRE) — 12KB
- aqst-20241202_htm.xml (XML) — 3KB
01
Item 7.01 Regulation FD Disclosure. On December 2, 2024, Aquestive Therapeutics, Inc. (the "Company") issued a press release announcing receipt of positive feedback from the U.S. food and Drug Administration prior to its New Drug Application (NDA) submission for Anaphylm (epinephrine) Sublingual Film and reaffirmed NDA submission guidance in the first quarter of 2025. A copy of the press release is filed as Exhibit 99.1 hereto and incorporated into this Item 7.01 by reference. The information in this Item 7.01 (including Exhibit 99.1) shall not be deemed to be "filed" for purposes of, or otherwise subject to the liabilities of, Section 18 of the Exchange Act of 1934, as amended (the "Exchange Act"), nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in any such filing.
01
Item 8.01 Other Events. The Company is planning to present certain supplemental materials (the "Supplemental Materials") in meetings with institutional investors, analysts and others. A copy of the Supplemental Materials is attached hereto as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated into this Item 8.01 by reference.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d)Exhibits. Exhibit Number Description 99.1 Aquestive Therapeutics, Inc. Press Release, dated December 2, 2024 99.2 Anaphylm (epinephrine) Sublingual Film Pre-NDA Meeting Supplemental Materials, dated December 2024 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: December 2, 2024 Aquestive Therapeutics, Inc. By: /s/ A. Ernest Toth, Jr Name: A. Ernest Toth, Jr. Title: Chief Financial Officer